Login
$STRO
$9.32 -$0.50 (5.09%) Live

$STRO 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 –

12 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

– Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study –

08 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 5, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), and the following proposals were adopted:

14 May 2026 8-K: Results of Operations and Financial Condition

– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 –

23 Mar 2026 8-K: Termination of a Material Definitive Agreement; Results of Operations and Financial Condition

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 –

10 Feb 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

1. INTRODUCTORY. Sutro Biopharma, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, an “Underwri...

17 Dec 2025 8-K: Other Events

On December 17, 2025, Sutro Biopharma, Inc. (the “Company”) received notice from the Listing Qualifications staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Lis...

03 Dec 2025 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

SOUTH SAN FRANCISCO, Calif., Dec. 1, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it...

06 Nov 2025 8-K: Results of Operations and Financial Condition

– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end –

29 Sep 2025 8-K: Costs Associated with Exit or Disposal Activities

SOUTH SAN FRANCISCO, Calif., September 29, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced an organization...

07 Aug 2025 8-K: Results of Operations and Financial Condition

– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 –

25 Jun 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

10 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 6, 2025, the Company held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), and the following proposals were adopted:

02 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation

Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

08 May 2025 8-K: Results of Operations and Financial Condition

- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization -

14 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation

On April 10, 2025, John Freund, M.D., a member of the Board of Directors (the “Board”) of Sutro Biopharma, Inc., a Delaware corporation (the “Company”) since 2014, informed the Board of his decision to not stand for re-election to the Bo...

13 Mar 2025 8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities +1 more

–Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition–

10 Dec 2024 8-K: Other Events

On December 10, 2024, Sutro Biopharma, Inc. (the “Company”) announced the selected dose from the dose-optimization portion (Part 1) of REFRαME-O1, the registration-directed trial of luveltamab tazevibulin (“luvelta”), a novel folate rece...

13 Nov 2024 8-K: Results of Operations and Financial Condition

- Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology -

13 Aug 2024 8-K: Results of Operations and Financial Condition

- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 -

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support